Propranolol is a non-selective beta-adrenergic antagonist and naphthalene derivative first approved by the FDA in 1967. It is prescribed for a broad range of conditions including hypertension, essential tremor, migraine prophylaxis, and anxiety. As a racemic mixture, its S(-)-enantiomer demonstrates roughly 100 times greater binding affinity for beta-adrenergic receptors than its counterpart, accounting for most of its pharmacological activity.
Propranolol molecular structure diagram from the DrugsPRO substance library.
Also known as: Sumial, Ciplar, Inderal, Deralin, Dociton, Inderal LA, Innopran XL, Hemangeol, Hemangiol
Classification
Chemical: Medicine
Psychoactive: Depressant
Tag: Anxiolytic
Tag: Beta-adrenergic antagonist
Tag: Common
Tag: Naphthalene derivative
Tag: Pharmaceutical
Effects
Decreased Heart Rate
Decreased Blood Pressure
Sedation
Reduced Heart Rate
Lowered Blood Pressure
Tremor
Anxiety Suppression
Dream Potentiation
Dizziness
Anxiety
Vivid Dreams
Sadness
Routes of Administration
Oral
Dosage
Heavy: 160+ mg
Light: 10 – 30 mg
Common: 30 – 80 mg
Strong: 80 – 140 mg
Threshold: 10 mg
Duration
Onset: 0.17-0.75 h
After Effects: 1-8 h
Peak: 1-4 h
Offset: 6-12 h
Total Duration: 6-12 h
Intravenous
Dosage
Heavy: 20+ mg
Light: 1-2 mg
Common: 2-10 mg
Strong: 10-20 mg
Threshold: 1 mg
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Propranolol - DrugsPRO gwida tal-sustanza
Propranolol: Propranolol is a non-selective beta-adrenergic antagonist and naphthalene derivative first approved by the FDA in 1967. It is prescribed for a broad range of conditions including hypertension, essential tremor, migraine prophylaxis, and anxiety. As a racemic mixture, its S(-)-enantiomer